European Pharmaceutical Review

FEBRUARY 14, 2024

Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles. About the authors Mike Frodsham has been the Chief Technical Officer for SGS Quay Pharma for over 18 years and holds over 23 years of experience in drug product development. 2015; 69(1):381–403 5. 2021; 19:100306 4.

Food and Drug Administration 80

Food and Drug Administration Manufacturing Engineering Pharmacology 80

European Pharmaceutical Review

JANUARY 18, 2024

The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. Comparatively, in 2015, GlobalData’s research expected that sales of therapies for Gaucher disease will reach $1.16 percent from $3.2 billion in 2022 to $4.1 billion in 2032. percent between 2022 and 2032.

Marketing 93

Marketing Sales Pharmacology Pharma 93

pharmaphorum

JANUARY 16, 2023

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. More approvals, in larger patient population conditions will elevate the ongoing discussion of how to pay for these therapies.

FDA 87

FDA Healthcare Healthcare Medicine 87

Pharmaceutical Technology

OCTOBER 10, 2022

After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD). Moreover, despite the buzz generated when Addyi was launched in 2015, only one other drug has since been marketed.

Pharmacology 59

Pharmacology Side effects FDA Safety 59